Outcomes of Tumor Necrosis Factor Inhibitor Cycling versus Switching to a Disease-modifying Anti-rheumatic Drug with a New Mechanism of Action Among Patients with Rheumatoid Arthritis
J Med Econ 2017;20:464–73
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Med Econ 2017;20:464–73
N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247
Arthritis Research & Therapy (2015) 17:319 DOI: 10.1186/s13075-015-0835-7
Arthritis Rheumatol. 2015 May 4. doi: 10.1002/art.39183. [Epub ahead of print]
Arthritis Res Ther. 2015 May 20;17(1):135. [Epub ahead of print]
Nature. 2015 Feb 16. doi: 10.1038/nature14154. [Epub ahead of print]
Nat Med. 2015 Feb 16. doi: 10.1038/nm.3806. [Epub ahead of print]
Arthritis Rheumatol. 2015;67(3):616-25.
Rheumatology (Oxford). 2014 Nov 17. pii: keu430. [Epub ahead of print]
Ann Rheum Dis. 2014 Nov 14. pii: annrheumdis-2014-206028. doi: 10.1136/annrheumdis-2014-206028. [Epub ahead of print]